Comparing Two Dialysis Methods for Children with Kidney Disease
Comparing Conventional Continuous Ambulatory Peritoneal Dialysis Prescription (C-CAPD) With Modified-CAPD (M-CAPD) Prescription in Children With End-stage Kidney Disease From Low-resource Settings
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
Ready to participate?
Review the details below, then apply to join this clinical trial.
At a Glance
Age
2 – 18
Sex
Any
Study type
Interventional
Purpose
Treatment
Participants needed
44 (estimated)
Sponsor
National University Health System, Singapore · Other
Who this trial is looking for
This trial is looking for children aged 2 to 18 who are on peritoneal dialysis for at least three months. Participants will compare two types of dialysis to see which is more effective for their kidney health.
Are You a Good Fit for This Trial?
You may be able to join if
I am between 2 and 18 years old
I have been on peritoneal dialysis for at least three months
I have end-stage kidney disease
You may not be able to join if
My body surface area is 1.5 m2 or greater
I have mechanical issues causing low dialysis efficiency
I have peritoneal membrane failure
I have had peritonitis in the last two months
I have switched from hemodialysis to peritoneal dialysis in the last three weeks
Summarized in plain language from this trial's official eligibility criteria.
The full criteria are further down this page — only the research team can
confirm whether you qualify.
Think this trial could be right for you?
Answer three quick questions written from this study's own rules to see if you may qualify. No account needed to find out.
This study aims to compare modified CAPD (M-CAPD) and conventional CAPD (C-CAPD) in terms of delivering high-quality, goal-directed PD as well as avoiding resource wastage in prevalent ESKD patients aged 2 to ≤18 years using a randomized cross-over study design for one year.
This study hypothesizes that M-CAPD will have better ultrafiltration and solute clearance than C-CAPD.
Specific objectives…
This study aims to compare modified CAPD (M-CAPD) and conventional CAPD (C-CAPD) in terms of delivering high-quality, goal-directed PD as well as avoiding resource wastage in prevalent ESKD patients aged 2 to ≤18 years using a randomized cross-over study design for one year.
This study hypothesizes that M-CAPD will have better ultrafiltration and solute clearance than C-CAPD.
Specific objectives
1. To determine the ultrafiltration efficiency by measuring the following:
1. Clinical parameters: blood pressure, weight, evidence of fluid overload by the presence of edema, abnormal heart sounds (S3 gallop), lung crackles or rales, increased heart rate (tachycardia), rapid breathing (tachypnea),
2. Change in the number of blood pressure medications before and after the intervention,
3. Absolute and relative fluid overload using bioimpedance analyzer (BIA),
4. Mean daily ultrafiltration (UF) or Total 24-h UF,
5. Residual kidney function: 24-hour urine output,
6. Glucose exposure
2. To determine the solute clearance adequacy by measuring the following:
1. Serum sodium, chloride, potassium, bicarbonate, serum albumin, calcium, and hemoglobin,
2. Phosphate clearance
3. Renal and peritoneal Kt/Vurea
4. Normalized protein catabolic rate (nPCR)
3. To measure caregiver burden using a Paediatric Renal Caregiver Burden Scale (PR-CBS).
Trial Locations
Loading…
Loading trial locations…
Facility
City
State
Country
Status
Eligibility Criteria
Inclusion Criteria:
* CKD 5D who have been on peritoneal dialysis for at least three months.
Exclusion Criteria:
1. Patients with BSA of ≥1.5 m2,
2. Evidence of mechanical causes of low ultrafiltration capacity (hernia, peri-catheter, or genital leaks, pleuroperitoneal communication),
3. Peritone…
Inclusion Criteria:
* CKD 5D who have been on peritoneal dialysis for at least three months.
Exclusion Criteria:
1. Patients with BSA of ≥1.5 m2,
2. Evidence of mechanical causes of low ultrafiltration capacity (hernia, peri-catheter, or genital leaks, pleuroperitoneal communication),
3. Peritoneal membrane failure (encapsulating peritoneal sclerosis),
4. Recent episode of peritonitis (within two months)
5. Those who have been on hemodialysis before switching to PD in the last three weeks.
Picking one helps us show the most relevant trials first.
Your results are loading in the background — you can
change this any time from the results page.
Set your location to continue
Find My Trials uses your location to surface clinical trials near you.
Add your city or zip code to your profile and try again.
